Is REPL or RXRX more undervalued in 2026?

CirclFi compares Replimune Group, Inc. (REPL) and Recursion Pharmaceuticals, Inc. (RXRX) using 13 institutional-grade valuation models. REPL has a Quality of Company score of 4.4/10 while RXRX scores 6.5/10.

Which is a better buy — REPL or RXRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do REPL and RXRX valuations compare?

REPL at $8.69 and RXRX at $3.59 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

REPL vs RXRX Valuation Comparison 2026 — Intrinsic Value Analysis

REPL

Biological Products, (No Diagnostic Substances)

Replimune Group, Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$8.69

Last close

Models

7/13

Active

RXRX

Biological Products, (No Diagnostic Substances)

Recursion Pharmaceuticals, Inc.

Quality

6.5

out of 10

Value Trap

LOW

Price

$3.59

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	REPL Fair Value	REPL Upside	RXRX Fair Value	RXRX Upside
Bayesian DCF	Intrinsic	$1.76	-79.8%	$1.39	-61.2%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$2.22	-74.5%	$0.04	-98.9%
Dynamic NAV	Asset-Based	$3.58	-58.8%	$1.99	-44.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for REPL vs RXRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

REPL vs RXRX — Which Stock Is More Undervalued?

RXRX scores higher with a 6.5/10 quality rating vs REPL's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Replimune Group, Inc. (REPL) and Recursion Pharmaceuticals, Inc. (RXRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

REPL currently trades at $8.69 with a QOC of 4.4/10, while RXRX trades at $3.59 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).